This application requests the continuation of support for the Pharmaceutical Research Center at Florida A&M University (FAMU). The overall objective of the RCMI Program at FAMU is to strengthen the biomedical research capabilities of the faculty to facilitate the entry into mainstream funding from the National Institutes of Health and other federal agencies. FAMU expects this to be accomplished during the requested cycle through the continual support of previously funded activities which has shown productivity and the development of three new contemporary activities. An important aspect of this effort is to continue as the leading institution in the education of minority doctoral students in the pharmaceutical sciences.
The specific aims of this program are to continue the advances within the research administration office, and the drug delivery and neuroscience research activities. We also are requesting the support for three new research activities in drug discovery; molecular biology; and applied research, technology, and information enhancements. The administrative office will continue to notify faculty of funding opportunities and provide pre- and post-award assistance, administrative oversight, word-processing, secretarial services and staff development. The RCMI support will allow FAMU to recruit and retain productive faculty with expertise in each of the above mentioned research activities. FAMU will continue to develop and strengthen its research environment which foster intra and inter-disciplinary research. In addition, the University will continue to sponsor nationally acclaimed scientists for research collaborations, workshops, and seminars, and provide development opportunities for junior faculty to enhance and stimulate interest in biomedical/behavioral research, as well as to develop skills in writing and submitting mainstream grant proposals. Health disparities in minority research will be the theme for the research and training in the program when appropriate.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003020-21
Application #
6899390
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Program Officer
Douthard, Regine
Project Start
1985-09-30
Project End
2008-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
21
Fiscal Year
2005
Total Cost
$2,022,902
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527
Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744
Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33
Archibong, Edikan; Foster, Alexander; Caldwell, Keirsten et al. (2016) Synthesis, characterization, and electrospinning of novel polyaniline-peptide polymers. Appl Mater Today 4:78-82
Ofori, Edward; Zhu, Xue Y; Etukala, Jagan R et al. (2016) Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands. Bioorg Med Chem 24:3464-71
Mathis, Arlesia; Rooks, Ronica; Kruger, Daniel (2016) Improving the Neighborhood Environment for Urban Older Adults: Social Context and Self-Rated Health. Int J Environ Res Public Health 13:ijerph13010003
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467
Etukala, Jagan R; Zhu, Xue Y; Eyunni, Suresh V K et al. (2016) Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem 24:3671-9

Showing the most recent 10 out of 204 publications